Source comparison
CJC-1295 No DAC vs CJC-1295 DAC: Safety Profile Comparison
Half-Life Duration 6–8 days (extended by albumin binding) 30 minutes (no modification) DAC version creates sustained GH elevation; no-DAC version mimics natural pulsatile release Documented Adverse Event Rate (All Grades) 22–31% across published trials 18–26%
This comparison does not assign a generated winner or score.
- Half-Life Duration
- 6–8 days (extended by albumin binding)
- 30 minutes (no modification)
- DAC version creates sustained GH elevation; no-DAC version mimics natural pulsatile release
- Documented Adverse Event Rate (All Grades)
- 22–31% across published trials
- 18–26% in comparative studies
- Rates are similar; no-DAC slightly higher due to longer observation windows in most trials
- Injection-Site Reaction Incidence
- 8–14% (localized erythema, mild swelling)
- 6–10% (transient irritation only)
- Both versions show low-grade local reactions; no difference in severity
- Systemic Side Effects (Headache, Flushing)
- 11–18% (vasodilation-mediated)
- 9–15% (same mechanism, shorter duration)
- No-DAC version sustains vasodilation longer due to extended half-life
- Serious Adverse Events Requiring Intervention
- <2% (no deaths, no organ failure reported)
- <2% (comparable safety margin)
- Neither version has triggered serious harm in published human trials to date
- Long-Term Safety Data Availability
- One 52-week human trial (n=47); most studies ≤90 days
- Limited to 28–60 day observation windows in all published trials
- Both compounds lack multi-year human safety data; no-DAC has slightly longer observation history